Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Adia Nutrition (OTC Pink: ADIA) has announced that its subsidiary, Adia Med, is exploring international expansion following significant interest from global healthcare entities. The company has received legal confirmation supporting its ability to operate clinics abroad and is evaluating a specific location outside the US for its first international facility.
The expansion focuses on delivering advanced treatments including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and umbilical cord blood stem cell therapies using their premier product, Adia Vita. Adia Med is currently one of only three clinic networks in the US offering this specialized technology.
The company is now conducting a comprehensive review of international regulations and requirements while developing strategic partnerships to facilitate market entry. The move aims to extend access to Adia Vita's regenerative medicine treatments, which have gained recognition for their potency and purity in treating various conditions from circulatory disorders to orthopedic applications.
Adia Nutrition (OTC Pink: ADIA) ha annunciato che la sua controllata, Adia Med, sta esplorando l'espansione internazionale a seguito di un notevole interesse da parte di enti sanitari globali. L'azienda ha ricevuto conferma legale a supporto della sua capacità di gestire cliniche all'estero ed è attualmente in fase di valutazione di una posizione specifica al di fuori degli Stati Uniti per la sua prima struttura internazionale.
L'espansione si concentra sulla fornitura di trattamenti avanzati, tra cui Scambio Terapeutico di Plasma (TPE), Trapianto di Cellule Staminali Ematopoietiche (HSCT) e terapie con cellule staminali da sangue cordonale utilizzando il loro prodotto di punta, Adia Vita. Adia Med è attualmente una delle sole tre reti cliniche negli Stati Uniti che offrono questa tecnologia specializzata.
L'azienda sta ora conducendo una revisione approfondita delle normative e dei requisiti internazionali mentre sviluppa partnership strategiche per facilitare l'ingresso nel mercato. Questa mossa mira ad estendere l'accesso ai trattamenti di medicina rigenerativa di Adia Vita, che hanno guadagnato riconoscimento per la loro potenza e purezza nel trattamento di varie condizioni, dai disturbi circolatori alle applicazioni ortopediche.
Adia Nutrition (OTC Pink: ADIA) ha anunciado que su filial, Adia Med, está explorando la expansión internacional tras un interés significativo de entidades de salud globales. La compañía ha recibido confirmación legal que respalda su capacidad para operar clínicas en el extranjero y está evaluando una ubicación específica fuera de EE. UU. para su primera instalación internacional.
La expansión se centra en ofrecer tratamientos avanzados, incluyendo Intercambio Terapéutico de Plasma (TPE), Transplante de Células Madre Hematopoyéticas (HSCT) y terapias con células madre de sangre de cordón umbilical utilizando su producto insignia, Adia Vita. Adia Med es actualmente una de solo tres redes clínicas en EE. UU. que ofrece esta tecnología especializada.
La compañía ahora está realizando una revisión exhaustiva de las regulaciones y requisitos internacionales mientras desarrolla asociaciones estratégicas para facilitar la entrada al mercado. Este movimiento tiene como objetivo extender el acceso a los tratamientos de medicina regenerativa de Adia Vita, que han ganado reconocimiento por su potencia y pureza en el tratamiento de diversas condiciones, desde trastornos circulatorios hasta aplicaciones ortopédicas.
아디아 뉴트리션 (OTC 핑크: ADIA)는 자회사인 아디아 메드가 글로벌 헬스케어 기관들로부터의 상당한 관심에 따라 국제 확장을 탐색하고 있다고 발표했습니다. 회사는 해외에서 클리닉을 운영할 수 있는 법적 확인을 받았으며, 첫 번째 국제 시설을 위해 미국 외의 특정 위치를 평가하고 있습니다.
확장은 치료적 혈장 교환 (TPE), 조혈모세포 이식 (HSCT), 제대혈 줄기 세포 치료를 포함한 고급 치료 제공에 중점을 두고 있으며, 이들은 그들의 주력 제품인 아디아 비타를 사용하고 있습니다. 아디아 메드는 현재 이 전문 기술을 제공하는 미국 내 세 개의 클리닉 네트워크 중 하나입니다.
회사는 이제 국제 규정 및 요건에 대한 종합적인 검토를 진행하고 있으며, 시장 진입을 용이하게 하기 위해 전략적 파트너십을 개발하고 있습니다. 이 조치는 아디아 비타의 재생 의학 치료에 대한 접근성을 확장하는 것을 목표로 하며, 이는 순도와 효능으로 인정받아 순환 장애부터 정형외과적 적용에 이르기까지 다양한 조건을 치료하는 데 사용되고 있습니다.
Adia Nutrition (OTC Pink: ADIA) a annoncé que sa filiale, Adia Med, explore une expansion internationale suite à un intérêt significatif de la part d'entités de santé mondiales. L'entreprise a reçu une confirmation légale soutenant sa capacité à exploiter des cliniques à l'étranger et évalue un emplacement spécifique en dehors des États-Unis pour sa première installation internationale.
L'expansion se concentre sur la fourniture de traitements avancés, y compris Échange Plasma Thérapeutique (TPE), Transplantation de Cellules Souches Hématopoïétiques (HSCT) et thérapies par cellules souches de sang de cordon ombilical en utilisant leur produit phare, Adia Vita. Adia Med est actuellement l'un des trois réseaux cliniques aux États-Unis offrant cette technologie spécialisée.
L'entreprise effectue maintenant un examen complet des réglementations et exigences internationales tout en développant des partenariats stratégiques pour faciliter l'entrée sur le marché. Ce mouvement vise à étendre l'accès aux traitements de médecine régénérative d'Adia Vita, qui ont été reconnus pour leur puissance et leur pureté dans le traitement de diverses conditions, des troubles circulatoires aux applications orthopédiques.
Adia Nutrition (OTC Pink: ADIA) hat bekannt gegeben, dass ihre Tochtergesellschaft, Adia Med, eine internationale Expansion in Betracht zieht, nachdem signifikantes Interesse von globalen Gesundheitsorganisationen geäußert wurde. Das Unternehmen hat eine rechtliche Bestätigung erhalten, die seine Fähigkeit unterstützt, Kliniken im Ausland zu betreiben, und evaluiert derzeit einen spezifischen Standort außerhalb der USA für seine erste internationale Einrichtung.
Die Expansion konzentriert sich auf die Bereitstellung fortschrittlicher Behandlungen, einschließlich Therapeutischem Plasmaaustausch (TPE), Hämatopoetischer Stammzelltransplantation (HSCT) und Therapien mit Nabelschnurblut-Stammzellen unter Verwendung ihres Hauptprodukts, Adia Vita. Adia Med ist derzeit eines von nur drei Kliniknetzwerken in den USA, die diese spezialisierte Technologie anbieten.
Das Unternehmen führt nun eine umfassende Überprüfung der internationalen Vorschriften und Anforderungen durch, während es strategische Partnerschaften entwickelt, um den Markteintritt zu erleichtern. Dieser Schritt zielt darauf ab, den Zugang zu den regenerativen Medizinbehandlungen von Adia Vita zu erweitern, die für ihre Wirksamkeit und Reinheit bei der Behandlung verschiedener Erkrankungen von Kreislauferkrankungen bis hin zu orthopädischen Anwendungen anerkannt sind.
- Legal approval secured for international expansion
- Specific location already identified for first international clinic
- One of only three US clinic networks with specialized treatment technology
- Strong global demand for company's treatments and Adia Vita product
- International expansion still in planning phase with no definitive timeline
- Regulatory compliance requirements across different countries may delay implementation
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243471__bf477173-b44d-457c-bb35-7984f21e1815.jpg
Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States.
"We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach."
Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity.
While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders.
For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit www.adiamed.com or contact ceo@adiamed.com.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243471
FAQ
What international expansion plans has Adia Nutrition (ADIA) announced in March 2025?
What key treatments does Adia Med (ADIA) offer in its clinics?
How unique is Adia Med's (ADIA) treatment technology in the US market?
What medical conditions can Adia Med's (ADIA) Adia Vita treatment target?
